Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity

Journal of Immunology

Volumn 182, Issue 9, 2009, Pages 5873-5881

  Jacob, Jennifer B ^a   Kong, Yi Chi M ^b   Nalbantoglu, Ilke ^c   Snower, Daniel P ^c   Wei, Wei Zen ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; THYROGLOBULIN; CANCER VACCINE; ERBB2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE THYROIDITIS; AUTOIMMUNITY; BAGG ALBINO MOUSE; BREAST TUMOR; CANCER GROWTH; CANCER PREVENTION; CONTROLLED STUDY; DNA IMMUNIZATION; DRUG EFFECT; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RISK ASSESSMENT; T CELL DEPLETION; TRANSGENIC MOUSE; TUMOR IMMUNITY; TUMOR REGRESSION; ANIMAL; CELL STRAIN 3T3; EXPERIMENTAL NEOPLASM; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; LYMPHOCYTE DEPLETION; METHODOLOGY; PATHOLOGY; RAT; REMISSION; TUMOR CELL LINE;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; LYMPHOCYTE DEPLETION; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; NIH 3T3 CELLS; RATS; RECEPTOR, ERBB-2; REMISSION INDUCTION; T-LYMPHOCYTES, REGULATORY; THYROGLOBULIN; THYROIDITIS, AUTOIMMUNE; VACCINES, DNA;

EID: 66949176637     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0804074     Document Type: Article

References (29)

1. Gogas, H., J. Ioannovich, U. Dafni, C. Stavropoulou-Giokas, K. Frangia, D. Tsoutsos, P. Panagiotou, A. Polyzos, O. Papadopoulos, A. Stratigos, et al. 2006. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354: 709-718. (Pubitemid 43247141)
2. McNeel, D. G., K. L. Knutson, K. Schiffman, D. R. Davis, D. Caron, and M. L. Disis. 2003. Pilot study of an HLA-A2 peptide vaccine using flt3 ligand as a systemic vaccine adjuvant. J. Clin. Immunol. 23: 62-72.
3. Okayasu, I., Y. Hara, K. Nakamura, and N. R. Rose. 1994. Racial and age-related differences in incidence and severity of focal autoimmune thyroiditis. Am. J. Clin. Pathol. 101: 698-702. (Pubitemid 24169300)
4. Jacobson, D. L., S. J. Gange, N. R. Rose, and N. M. Graham. 1997. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 84: 223-243.
5. Takamatsu, J., S. Yoshida, T. Yokozawa, K. Hirai, K. Kuma, N. Ohsawa, and T. Hosoya. 1998. Correlation of antithyroglobulin and antithyroid-peroxidase antibody profiles with clinical and ultrasound characteristics of chronic thyroiditis. Thyroid 8: 1101-1106. (Pubitemid 29042542)
6. Huang, W., and G. D. Kukes. 1999. Hashimoto's thyroiditis: an organ-specific autoimmune disease: pathogenesis and recent developments. Lab. Invest. 79: 1175-1180. (Pubitemid 29489443)
7. Canonica, G. W., M. E. Cosulich, R. Croci, S. Ferrini, M. Bagnasco, W. Dirienzo, O. Ferrini, A. Bargellesi, and G. Giordano. 1984. Thyroglobulin- induced T-cell in vitro proliferation in Hashimoto's thyroiditis: identification of the responsive subset and effect of monoclonal antibodies directed to Ia antigens. Clin. Immunol. Immunopathol. 32: 132-141.
8. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377. (Pubitemid 36842552)
9. Blansfield, J. A., K. E. Beck, K. Tran, J. C. Yang, M. S. Hughes, U. S. Kammula, R. E. Royal, S. L. Topalian, L. R. Haworth, C. Levy, et al. 2005. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J. Immunother. 28: 593-598.
10. Maker, A. V., P. Attia, and S. A. Rosenberg. 2005. Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade. J. Immunol. 175: 7746-7754.
11. + regulatory T cell-depleted mice. Cancer Res. 65: 8471-8478.
12. Kong, Y. M., L. C. Lomo, R. W. Motte, A. A. Giraldo, J. Baisch, G. Strauss, G. J. Hammerling, and C. S. David. 1996. HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA-DRB1*0301 (DR3) gene. J. Exp. Med. 184: 1167-1172. (Pubitemid 26313574)
13. Jacob, J. B., Y. M. Kong, C. Meroueh, D. P. Snower, C. S. David, Y. S. Ho, and W. Z. Wei. 2007. Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res. 67: 7020-7027.
14. Lucchini, F., M. G. Sacco, N. Hu, A. Villa, J. Brown, L. Cesano, L. Mangiarini, G. Rindi, S. Kindl, F. Sessa, et al. 1992. Early and multifocal tumors in breast, salivary, harderian and epididymal tissues developed in MMTY-Neu transgenic mice. Cancer Lett. 64: 203-209.
15. Boggio, K., G. Nicoletti, C. E. Di, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I. Rossi, P. Nanni, G. C. De, et al. 1998. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188: 589-596. (Pubitemid 28369147)
16. Rovero, S., A. Amici, E. Di Carlo, R. Bei, P. Nanni, E. Quaglino, P. Porcedda, K. Boggio, A. Smorlesi, P. L. Lollini, et al. 2000. Inhibition of carcinogenesis by DNA vaccination. J. Immunol. 165: 5133-5142.
17. Nanni, P., S. M. Pupa, G. Nicoletti, G. C. De, L. Landuzzi, I. Rossi, A. Astolfi, C. Ricci, V. R. De, A. M. Invernizzi, et al. 2000. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int. J. Cancer 87: 186-194. (Pubitemid 30434343)
18. Jacob, J., O. Radkevich, G. Forni, J. Zielinski, D. Shim, R. F. Jones, and W. Wei. 2006. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol. 240: 96-106. (Pubitemid 44353445)
19. Miller, F., R. F. Jones, J. Jacob, Y. M. Kong, and W. Z. Wei. 2004. From breast cancer immunobiology to her-2 DNA vaccine and autoimmune sequelae. Breast Dis. 20: 43-51. (Pubitemid 39600445)
20. Pilon, S. A., C. Kelly, and W. Z. Wei. 2003. Broadening of epitope recognition during immune rejection of ErbB-2-positive tumor prevents growth of ErbB-2-negative tumor. J. Immunol. 170: 1202-1208.
21. Piechocki, M. P., S. A. Pilon, and W. Z. Wei. 2002. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J. Immunol. Methods 259: 33-42.
22. Kong, Y. M., C. S. David, A. A. Giraldo, M. Elrehewy, and N. R. Rose. 1979. Regulation of autoimmune response to mouse thyroglobulin: influence of H-2D-end genes. J. Immunol. 123: 15-18.
23. Kong, Y. M. 2007. Experimental autoimmune thyroiditis in the mouse. In Current Protocols in Immunology. J. E. Coligan, B. E. Bierer, D. H. Margulies, E. M. Shevach, and W. Strober, eds. John Wiley and Sons, New York, p. 15.7.1-15.7.21.
24. Elrehewy, M., Y. M. Kong, A. A. Giraldo, and N. R. Rose. 1981. Syngeneic thyroglobulin is immunogenic in good responder mice. Eur. J. Immunol. 11: 146-151.
25. Zhang, W., J. C. Flynn, and Y. M. Kong. 2001. IL-12 prevents tolerance induction with mouse thyroglobulin by priming pathogenic T cells in experimental autoimmune thyroiditis: role of IFN-γ and the costimulatory molecules CD40L and CD28. Cell Immunol. 208: 52-61. (Pubitemid 32299660)
26. Spadaro, M., E. Ambrosino, M. Iezzi, E. Di Carlo, P. Sacchetti, C. Curcio, A. Amici, W. Z. Wei, P. Musiani, P. L. Lollini, et al. 2005. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immunity. Clin. Cancer Res. 11: 1941-1952. (Pubitemid 40471860)
27. + regulatory T cells in induced tolerance to experimental autoimmune thyroiditis. Cell Immunol. 226: 20-29.
28. + regulatory T cells influence susceptibility but do not supersede MHC class II restriction. Front. Biosci. 11: 1234-1243.
29. Radkevich-Brown, O., J. Jacob, M. Kershaw, and W.-Z. Wei. 2009. Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice. Cancer Res. 69: 212-218.